Showing 631-640 of 5154 results for "".
The State of Academic Dermatology
https://practicaldermatology.com/topics/practice-management/the-state-of-academic-dermatology/18843/In this edition of Derm Insider, host Neal Bhatia, MD sits down with Jane Grant-Kels, MD, Sheila Fallon Friedlander, MD, and Kevin Cooper, MD to discuss the challenges and rewards of academic dermatology. From meeting aggressive budgets to dealing with EMRs, academicians face many of the same demandAssessing the Aging Face
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/assessing-the-aging-face/18849/Jason Emer, MD discusses the evolving filler market and new trends in facial rejuvenation treatments. He offers tips for assessing patients globally—in three and four dimensions—in order to choose the right options for contouring the face with fillers and fat in order to give patients the most naturLet's Talk about YouTube and why your Practice should have one
https://practicaldermatology.com/topics/practice-management/let-s-talk-about-youtube-and-why-your-practice-should-have-one/19116/Any form of healthcare, dental and veterinarian practice should have a YouTube account. It is known that people prefer to watch a video to learn and understand something, rather than read an article or look at a picture. YouTube gives your practice the chance to educate your patients or clients.DermWireTV Update
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-update/19125/Allergan is business as usual following a revised merger offer from Valeant. Get an update on the offer and Allergan's recent nominationfor the Prixe Galien USA.DermwireTV — Bayer Buys Merck’s OTC Lines, Allergan Rejects Valeant Bid
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-bayer-buys-merck-rsquo-s-otc-lines-allergan-rejects-valeant-bid/19134/Bayer Purchases Merck's OTC Products and Allergan Rebuffs Valeant. This week DermWireTV explores Bayer's growth in the OTC space, including sunscreens, and reports new data on skin cancer mortality. Also in this edition: Neal Bhatia, MD reviews the Noah Worcester Society Annual Meeting.Medlite - What Physicians are Saying
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/medlite-what-physicians-are-saying/19453/Impressive statements from Doctors using the Medlite laser are given. The benefits and outcomes of specific cases are discussed.Part 1, 1726 nm lasers: Five dermatologists discuss the laser’s benefits and drawbacks for treating acne and other skin conditions
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24339/Chapter 1 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how they have brought in the new 1726 nm wavelength lasers into their practices, what skin conditions it is most benHow Early Experience With PDT Can Provide Career Pathways
https://practicaldermatology.com/series/pdt-in-practice/how-early-experience-with-pdt-can-provide-career-pathways/20212/Adam Friedman, MD, professor and chair of dermatology at George Washington University, discusses how early-career experience with photodynamic therapy, including exposure to doctor-mentors in the field, gave him professional skills and connections that prepared him for later-career opportunities.Tips for Success with Fillers
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/tips-for-success-with-fillers/20149/Heidi Waldorf, MD offers tips for getting the best results possible with fillers. From how to evaluate what patients need to considering shapes and proportions, she offers hands-on advice to help achieve optimal outcomes. Plus, she discusses the importance of managing patient expectations.Identifying SCC Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/identifying-scc-risk/20144/Sherrif Ibrahim, MD discusses the challenges of managing squamous cell carcinoma (SCC). Great steps have been made in clinical, pathological staging systems, but Dr. Ibrahim says it’s still difficult to determine what to do with borderline cases. He talks about the need to determine frequency and in